Results 61 to 70 of about 448 (162)
Journal of Immunology Research, Volume 2026, Issue 1, 2026.The identification of novel compounds capable of stimulating or suppressing immune responses is critical for advancing immunotherapy and improving our understanding of immune regulation. However, traditional screening approaches are often limited by low throughput, poor physiological relevance, and insufficient resolution to detect subtle ...
Regine Brox +2 more
wiley +1 more source
Clinical Otolaryngology, Volume 44, Issue 6, Page 997-1003, November 2019., 2019 Abstract Objectives The aim of the current study was to investigate the effectiveness and clinical feasibility of Biyeom‐go for the treatment of nasal symptoms associated with rhinitis. Design Prospective observational study. Setting This study was conducted at the Woosuk Korean Medicine Medical Center in South Korea.
Mi Ju Son +11 more
wiley +1 more source
Usefulness and Safety of Bepotastine Besilate for Pruritic Skin Disorders
Nishi Nihon Hifuka, 2006 ベシル酸ベポタスチンは鎮静効果が比較的弱く，即効性のある薬剤として各種そう痒性皮膚疾患に使用されている。今回，91例のそう痒性皮膚疾患に対してベシル酸ベポタスチンを投与し，その前後でVASスケールを用いてそう痒および眠気の推移について検討した。そう痒に関して投与前の平均VASスコアは60.6から投与1週間後では24.9と有意にスコアの低下がみられ，その効果は8週間投与観察期間中持続した。一方，眠気についてはベシル酸ベポタスチン内服後VASスコアの有意な上昇はみられなかった。また，投与前そう痒が強く，睡眠が障害され，投与前の眠気VASスコアが上昇していた症例では，ベシル酸ベポタスチン投与によるそう痒の改善から有意に眠気のVASスコアの改善がみられた ...
Hidetoshi TAKAHASHI, Hajime IIZUKA
openaire +2 more sources
Improvement of Dupilumab‐Induced Psoriasiform Eruption Following a Switch to Tralokinumab
JEADV Clinical Practice, Volume 4, Issue 5, Page 1210-1215, December 2025.ABSTRACT Biologic therapies have transformed the management of atopic dermatitis (AD) and prurigo nodularis (PN), yet paradoxical adverse events such as dupilumab‐induced psoriasiform eruption (DPE) are increasingly recognized. We report a 48‐year‐old Japanese man with long‐standing AD and PN who developed scaly, erythematous plaques on the elbows ...
Masato Mizuashi, Yoshinori Sasaki
wiley +1 more source
Clinical Ophthalmology, 2012 Craig F McCabe, Shannon E McCabeMcCabe Vision Center, Murfreesboro, TN, USABackground: The aim of this study was to compare patient-perceived relief of ocular itch, nasal symptoms, and eye drop comfort when allergic conjunctivitis was treated with ...
McCabe CF, McCabe SE
doaj
Advanced Synthesis &Catalysis, Volume 367, Issue 17, September 26, 2025.A mild and versatile strategy enabling the divergent synthesis of α‐fluoroamides and α‐aminoacyl fluorides from 2‐bromo‐2,2‐difluoro alcohols and amines is developed. The reaction shows broad scope and operational simplicity. Mechanistic and density functional theory studies support the formation of a putative gem‐difluoroepoxide intermediate ...
Giulia De Santis +8 more
wiley +1 more source
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Allergy, Volume 79, Issue 6, Page 1501-1515, June 2024.Abstract Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti‐interleukin‐4 receptor (IL‐4R) α in 2017), tralokinumab (anti‐IL‐13 in 2021), lebrikizumab (anti‐IL‐13 in 2023 ...
Svenja Müller +2 more
wiley +1 more source
Immediate Clinical Effectiveness of Bepotastine Besilate for Patients with Urticaria
Nishi Nihon Hifuka, 2006 蕁麻疹患者25例を対象として，ベシル酸ベポタスチン錠(タリオン®錠)の即効性と有用性に関するアンケート調査を行なった。即効性(内服後痒みの抑制効果を自覚した時間)に関しては回答を得た20例で，全例が内服後90分以内に痒みの抑制効果を自覚していた(内服後30分以内が50％，内服後60分以内が89％)。また92％以上が何らかの有効性を自覚していた。効果の持続時間に関しては，回答を得た19例で，4時間が16％，8時間32％，12時間が47％という結果であった。眠気の副作用は33％に認められたが，84％の患者は再処方を希望したことから，本剤の高い有用性が示された。
KOHDA, Futoshi +2 more
openaire +1 more source
Journal of Clinical Ophthalmology and ResearchPurpose: The purpose is to study the clinical presentation of seasonal allergic conjunctivitis (SAC) and treatment response to different therapies. Methods: This hospital-based comparative study included all patients aged over 10 years old diagnosed with
Srilekha Berelli +2 more
doaj +1 more source
Case Reports in Pediatrics, Volume 2024, Issue 1, 2024.Orofacial granulomatosis (OFG) is a rare disease entity characterized by nonnecrotizing granulomatous inflammation in the oral and maxillofacial regions, typically characterized by recurrent or persistent edema, primarily in the lips and occasionally in the gingiva. OFG is often associated with Crohn’s disease and sarcoidosis, and an accurate diagnosis
Taku Kimura +7 more
wiley +1 more source